116 related articles for article (PubMed ID: 15048958)
21. Rapid pre-screening of cervical smears as a method of internal quality control in a cervical screening programme.
Tavares SB; de Sousa NL; Manrique EJ; de Albuquerque ZB; Zeferino LC; Amaral RG
Cytopathology; 2008 Aug; 19(4):254-9. PubMed ID: 18476988
[TBL] [Abstract][Full Text] [Related]
22. In-house quality assurance program in a state cytology laboratory.
Gardner NM
Acta Cytol; 1989; 33(4):487-8. PubMed ID: 2750439
[TBL] [Abstract][Full Text] [Related]
23. The challenge of quality improvement with the Papanicolaou smear.
Kline TS
Arch Pathol Lab Med; 1997 Mar; 121(3):253-5. PubMed ID: 9111111
[TBL] [Abstract][Full Text] [Related]
24. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology.
Herbert A; Bergeron C; Wiener H; Schenck U; Klinkhamer P; Bulten J; Arbyn M
Cytopathology; 2007 Aug; 18(4):213-9. PubMed ID: 17635161
[TBL] [Abstract][Full Text] [Related]
25. Weekly rescreening of 10% of the total cervical Papanicolaou smears: a worthwhile quality assurance scheme.
Sampatanukul P; Wannakrairot P; Promprakob U; Yodavudh S; Anansiriprapa C
J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S261-5. PubMed ID: 16083199
[TBL] [Abstract][Full Text] [Related]
26. Dutch solutions for liquid-based cytology: analysis of unsatisfactory slides and HPV testing of equivocal cytology.
Boon ME; Rijkaart DC; Ouwerkerk-Noordam E; Korporaal H
Diagn Cytopathol; 2006 Sep; 34(9):644-8. PubMed ID: 16900471
[TBL] [Abstract][Full Text] [Related]
27. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience.
Sepúlveda C; Prado R
Cancer Detect Prev; 2005; 29(5):405-11. PubMed ID: 16188399
[TBL] [Abstract][Full Text] [Related]
28. A peer comparison program for the quality assurance of human papillomavirus DNA detection using the Digene Hybrid Capture II/SurePath method shows excellent analytic interlaboratory correlation.
Kuebler DL; Illingworth A; Blenc AM; Wilbur DC
Cancer; 2007 Oct; 111(5):339-43. PubMed ID: 17879373
[TBL] [Abstract][Full Text] [Related]
29. Organisation of cervical cytology screening in Croatia: past, present and future.
Pajtler M; Audy-Jurković S; Kardum-Skelin I; Mahovlić V; Mozetic-Vrdoljak D; Ovanin-Rakić A
Coll Antropol; 2007 Apr; 31 Suppl 2():47-54. PubMed ID: 17598505
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of 100% rapid rescreening of negative cervical smears as a quality assurance measure.
Manrique EJ; Amaral RG; Souza NL; Tavares SB; Albuquerque ZB; Zeferino LC
Cytopathology; 2006 Jun; 17(3):116-20. PubMed ID: 16719853
[TBL] [Abstract][Full Text] [Related]
31. Setting standards for cervical screening fail-safe mechanisms: a target based on an audit of cytopathology laboratory records.
Roberts E; Cook GA; Walsworth-Bell JP; Barrow S
J Med Screen; 1995; 2(2):102-4. PubMed ID: 7497153
[TBL] [Abstract][Full Text] [Related]
32. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
[TBL] [Abstract][Full Text] [Related]
33. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?
Wright TC
Clin Obstet Gynecol; 2007 Jun; 50(2):313-23. PubMed ID: 17513921
[TBL] [Abstract][Full Text] [Related]
34. Cervical cancer screening programs in Latin America and the Caribbean.
Murillo R; Almonte M; Pereira A; Ferrer E; Gamboa OA; Jerónimo J; Lazcano-Ponce E
Vaccine; 2008 Aug; 26 Suppl 11():L37-48. PubMed ID: 18945401
[TBL] [Abstract][Full Text] [Related]
35. Interlaboratory quality control in gynecologic cytopathology using the novel CONQUISTADOR software. Interobserver reproducibility in the Latin American screening study.
Alderisio M; Branca M; Erzen M; Longatto-Filho A; Derchain S; Tatti S; Vighi S; Roteli-Martins C; Leoncini L; Maeda MY; Montis D; Gontijo R; Sarian LO; Syrjänen K
Acta Cytol; 2007; 51(6):872-81. PubMed ID: 18077979
[TBL] [Abstract][Full Text] [Related]
36. [HPV test for quality control of gynecologic cytological tests].
Wilander E; Wikström I
Lakartidningen; 2008 Nov 26-Dec 9; 105(48-49):3560, 3564. PubMed ID: 19133586
[No Abstract] [Full Text] [Related]
37. Smear tests: déjà vu.
Nottingham J
BMJ; 2001 Sep; 323(7311):517. PubMed ID: 11560149
[No Abstract] [Full Text] [Related]
38. Cytopathology in Austria.
Breitenecker G; Dinges HP; Regitnig P; Wiener H; Vutuc Ch
Cytopathology; 2004 Apr; 15(2):113-8. PubMed ID: 15056173
[TBL] [Abstract][Full Text] [Related]
39. [The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening].
Berkers LM; van Ballegooijen M; van Kemenade FJ; Rebolj M; Essink-Bot ML; Helmerhorst TJ; Habbema JD
Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1288-94. PubMed ID: 17624160
[TBL] [Abstract][Full Text] [Related]
40. The false-negative fraction: a statistical method to measure the efficacy of cervical smear screening laboratories.
Dolinar J; Ollayos CW; Tellado M; Ali I; Stevens A; Paquette C; Brodbelt S
Mil Med; 1999 Jun; 164(6):410-1. PubMed ID: 10377709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
